Promore Pharma Promore Pharma carries out a rights issue of approximately SEK 75 million, underwritten up to 80 percent, and intends to publish its interim report early
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE US, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE CONTRAVENING TO ANY APPLICABLE RULES. The Board of Directors of Promore Pharma AB (publ) ("Promore Pharma" or the “Company") has resolved to carry out a new share issue with preferential rights for the Company's existing shareholders of a total of SEK 75 million excluding transaction costs (the “Rights Issue"). The Rights Issue is guaranteed up to 80 percent through subscription